Created: 22 December 2010
Published: 22 December 2010
The QAP asks laboratories to report results of 100 consecutive ER (oestrogen receptor)and PR (progesterone receptor) results on an annual basis. Recent survey results reveal that a small number of laboratories report as little as 50% positive, which seriously underestimates the occurrence of receptor positivity in breast cancer and deny women with a false negative result treatment with anti-oestrogen drugs like Tamoxifen.
Assessors participating in assessments of laboratories performing this testing are requested to review the results of this survey and if positivity rates are low to investigate the corrective action that has been undertaken.